Scholar Rock Revenue and Competitors
Estimated Revenue & Valuation
- Scholar Rock's estimated annual revenue is currently $18.2M per year.
- Scholar Rock received $47.0M in venture funding in January 2018.
- Scholar Rock's estimated revenue per employee is $111,656
- Scholar Rock's total funding is $153M.
- Scholar Rock's current valuation is $710.2M. (January 2022}
- Scholar Rock has 163 Employees.
- Scholar Rock grew their employee count by 12% last year.
Scholar Rock Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Scholar Rock?
Scholar Rock® is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.keywords:Biotechnology,Healthcare,Healthcare Providers,Pharmaceuticals
Number of Employees
Employee Growth %
Scholar Rock News
Scholar Rock, a Cambridge, Mass.-based biotechnology company focused on discovering and developing drugs that selectively modulate growth factor activation in the disease microenvironment, closed a $47m Series C financing. The round was led by new investor Invus, with participation from new inv ...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an oral presentation of TOPAZ Phase 2 trial results by the lead principal investigator, Thom ...
CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,130,803, ...
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise.
CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical ...
CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Scholar Rock Funding
|2014-09-16||$20.0M||A||ARCH Venture Partners||Article|
|2016-01-05||$36.0M||B||Fidelity Management and Research Company||Article|